Celecoxib exhibits antifungal effect against Paracoccidioides brasiliensis both directly and indirectly by activating neutrophil responses
- PMID: 38963980
- DOI: 10.1016/j.intimp.2024.112606
Celecoxib exhibits antifungal effect against Paracoccidioides brasiliensis both directly and indirectly by activating neutrophil responses
Abstract
Background: Celecoxib, an anti-inflammatory drug, combined therapies using antimicrobials and immune modulator drugs are being studied.
Objective: To assess whether Celecoxib has direct in vitro antifungal effect against the Paracoccidioides brasiliensis, the causative agent of Paracoccidioidomycosis-(PCM) and also if it improves the in vivo activity of neutrophils-(PMN) in an experimental murine subcutaneous-(air pouch) model of the disease.
Methods: The antifungal activity of Celecoxib(6 mg/mL) on P. brasiliensis-(Pb18) was evaluated using the microdilution technique. Splenocytes co-cultured with Pb18 and treated with Celecoxib(6 mg/mL) were co-cultured for 24, 48 and 72-hours. Swiss mice were inoculated with Pb18 and treated with Celecoxib(6 mg/kg) in the subcutaneous air pouch. Neutrophils were collected from the air pouch. Mitochondrial activity, reactive oxygen production, catalase, peroxidase, cytokines and chemokines, nitrogen species, total protein, microbicidal activity of PMNs and viable Pb18 cells numbers were analyzed.
Results: Celecoxib had no cytotoxic effect on splenocytes co-cultured with Pb18, but had a marked direct antifungal effect, inhibiting fungal growth both in vitro and in vivo. Celecoxib interaction with immune system cells in the air pouch, it leads to activation of PMNs, as confirmed by several parameters (mitochondrial activity, reactive oxygen species, peroxidase, KC and IL-6 increase, killing constant and phagocytosis). Celecoxib was able to reduce IL-4, IL-10 and IL-12 cytokine production. The number of recovered viable Pb18 decreased dramatically.
Conclusions: This is the first report of the direct antifungal activity of Celecoxib against P. brasiliensis. The use of Celecoxib opens a new possibility for future treatment of PCM.
Keywords: Celecoxib; Drug repurposing; Experimental model; Paracoccidioides brasiliensis; Paracoccidioidomycosis.
Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Brazilian Red Propolis shows antifungal and immunomodulatory activities against Paracoccidioides brasiliensis.J Ethnopharmacol. 2021 Sep 15;277:114181. doi: 10.1016/j.jep.2021.114181. Epub 2021 May 12. J Ethnopharmacol. 2021. PMID: 33991639
-
Itraconazole and neutrophil interactions in the immune-inflammatory response of paracoccidioidomycosis using a murine air pouch infection model.Life Sci. 2023 Feb 15;315:121371. doi: 10.1016/j.lfs.2023.121371. Epub 2023 Jan 5. Life Sci. 2023. PMID: 36621540
-
Binding of laminin to Paracoccidioides brasiliensis induces a less severe pulmonary paracoccidioidomycosis caused by virulent and low-virulence isolates.Microbes Infect. 2004 May;6(6):549-58. doi: 10.1016/j.micinf.2004.02.010. Microbes Infect. 2004. PMID: 15158188
-
Animal Models and Antifungal Agents in Paracoccidioidomycosis: An Overview.Mycopathologia. 2017 Aug;182(7-8):633-643. doi: 10.1007/s11046-017-0130-z. Epub 2017 Mar 21. Mycopathologia. 2017. PMID: 28324244 Review.
-
Paracoccidioides brasiliensis, paracoccidioidomycosis, and antifungal antibiotics.Curr Drug Targets Infect Disord. 2005 Sep;5(3):211-26. doi: 10.2174/1568005054880118. Curr Drug Targets Infect Disord. 2005. PMID: 16181141 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources